CL2008002399A1 - Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. - Google Patents

Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.

Info

Publication number
CL2008002399A1
CL2008002399A1 CL2008002399A CL2008002399A CL2008002399A1 CL 2008002399 A1 CL2008002399 A1 CL 2008002399A1 CL 2008002399 A CL2008002399 A CL 2008002399A CL 2008002399 A CL2008002399 A CL 2008002399A CL 2008002399 A1 CL2008002399 A1 CL 2008002399A1
Authority
CL
Chile
Prior art keywords
hepatitis
substantially pure
useful
treatment
carbon atoms
Prior art date
Application number
CL2008002399A
Other languages
English (en)
Inventor
Lin Ko-Chung
Original Assignee
Pharmaessentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351178&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaessentia Corp filed Critical Pharmaessentia Corp
Publication of CL2008002399A1 publication Critical patent/CL2008002399A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Conjugado sustancialmente puro que comprende por lo menos una porción polimérica, una porción proteica, y un ligante; método para preparar dicho conjugado proteína-polímero; método para tratar la infección por el virus de la hepatitis C o la infección por el virus de la hepatitis B.
CL2008002399A 2007-08-16 2008-08-14 Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. CL2008002399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95627307P 2007-08-16 2007-08-16

Publications (1)

Publication Number Publication Date
CL2008002399A1 true CL2008002399A1 (es) 2009-01-02

Family

ID=40351178

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002399A CL2008002399A1 (es) 2007-08-16 2008-08-14 Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.

Country Status (30)

Country Link
US (1) US8143214B2 (es)
EP (2) EP2205281B1 (es)
JP (1) JP5613050B2 (es)
KR (1) KR101588465B1 (es)
CN (1) CN101367872B (es)
AR (1) AR067964A1 (es)
AU (1) AU2008286742B2 (es)
BR (1) BRPI0814482B8 (es)
CA (1) CA2696478C (es)
CL (1) CL2008002399A1 (es)
CY (1) CY1125751T1 (es)
DK (1) DK2205281T3 (es)
EA (1) EA018111B1 (es)
ES (1) ES2924727T3 (es)
FR (1) FR22C1045I2 (es)
HR (1) HRP20220937T3 (es)
HU (2) HUE059551T2 (es)
LT (1) LT2205281T (es)
MX (1) MX2010001750A (es)
MY (1) MY149148A (es)
NL (1) NL301195I2 (es)
NO (1) NO2022038I1 (es)
NZ (1) NZ583831A (es)
PL (1) PL2205281T3 (es)
PT (1) PT2205281T (es)
SI (1) SI2205281T1 (es)
TW (1) TWI381851B (es)
UA (1) UA103158C2 (es)
WO (1) WO2009023826A1 (es)
ZA (1) ZA201001777B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104146C2 (ru) 2008-07-31 2014-01-10 Фармаиссеншиа Корп. ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
EP3215193B1 (en) 2014-11-06 2023-10-04 PharmaEssentia Corporation Dosage regimen for pegylated interferon
CN112433048A (zh) * 2020-11-17 2021-03-02 深圳上泰生物工程有限公司 一种用于化学发光免疫法的试剂盒及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
SK2942002A3 (en) * 1999-08-27 2002-08-06 Maxygen Aps A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use
KR20020065517A (ko) * 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002356990A1 (en) * 2001-11-20 2003-06-10 Pharmacia Corporation Chemically-modified human growth hormone conjugates
JP2005526151A (ja) 2002-01-18 2005-09-02 バイオゲン アイデック エムエー インク． 生物学的に活性な化合物の結合のための部分を有するポリアルキレングリコール
US7345150B2 (en) 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
AU2003270454B2 (en) 2002-09-09 2010-05-20 Nektar Therapeutics Water-soluble polymer alkanals
ES2725808T3 (es) * 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
EP1694347B1 (en) * 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
WO2006024953A2 (en) 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1869079A2 (en) * 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
ES2386575T3 (es) 2007-09-04 2012-08-23 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
ATE548382T1 (de) 2007-09-04 2012-03-15 Biosteed Gene Expression Tech Co Ltd Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
BRPI0814482B1 (pt) 2021-02-02
MY149148A (en) 2013-07-15
TWI381851B (zh) 2013-01-11
WO2009023826A1 (en) 2009-02-19
US8143214B2 (en) 2012-03-27
HRP20220937T3 (hr) 2022-09-30
US20090053177A1 (en) 2009-02-26
SI2205281T1 (sl) 2022-11-30
ES2924727T3 (es) 2022-10-10
JP5613050B2 (ja) 2014-10-22
NL301195I1 (es) 2022-08-31
KR20100076945A (ko) 2010-07-06
NO2022038I1 (no) 2022-09-02
PL2205281T3 (pl) 2022-12-12
EA201070282A1 (ru) 2010-08-30
CN101367872B (zh) 2013-11-20
EP2205281A1 (en) 2010-07-14
PT2205281T (pt) 2022-08-02
HUE059551T2 (hu) 2022-11-28
CA2696478C (en) 2018-10-09
NZ583831A (en) 2012-06-29
CA2696478A1 (en) 2009-02-19
CN101367872A (zh) 2009-02-18
AU2008286742A1 (en) 2009-02-19
TW200916116A (en) 2009-04-16
UA103158C2 (ru) 2013-09-25
KR101588465B1 (ko) 2016-01-25
CY1125751T1 (el) 2023-06-09
BRPI0814482A2 (pt) 2015-02-03
NL301195I2 (nl) 2023-03-02
DK2205281T3 (da) 2022-08-15
MX2010001750A (es) 2010-06-01
HUS2200039I1 (hu) 2022-09-28
EP4129343A1 (en) 2023-02-08
AR067964A1 (es) 2009-10-28
FR22C1045I1 (fr) 2022-10-14
JP2010536788A (ja) 2010-12-02
FR22C1045I2 (fr) 2023-12-29
EP2205281A4 (en) 2014-10-08
ZA201001777B (en) 2010-12-29
EA018111B1 (ru) 2013-05-30
BRPI0814482B8 (pt) 2021-11-23
EP2205281B1 (en) 2022-06-29
LT2205281T (lt) 2022-09-26
AU2008286742B2 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
BRPI0511834A (pt) métodos por tratar hepatite c
ECSP17064986A (es) Compuestos antivirales
ZA201001556B (en) Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ECSP10010210A (es) Compuestos nucleósidos antivirales
UY28581A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
CY1110506T1 (el) Χρηση των τροποποιημενων κυκλοσπορινων για τη θεραπεια των διαταραχων hcv
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
MX2010002909A (es) Metodo de tratamiento de pacientes de hepatitis c.
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
CL2008002399A1 (es) Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
UY29225A1 (es) Compuesto 5-nitro-nucleosidos para tratar infecciones virales
ATE555794T1 (de) Heilmittel gegen hepatitis
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
PH12020500176A1 (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
UA90477C2 (ru) Способ лечения гепатита с (варианты)
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators
CY1115326T1 (el) Φυτικη συνθεση για τη θεραπεια ή την προληψη ιογενων νοσων του αιματος, που προκαλουνται απο τον ιο της ανθρωπινης ανοσοανεπαρκειας (hiv) ή την ηπατιτιδα c
DK1613340T3 (da) Behandling af aspergillus-infektioner med thymosin alfa 1